がんバイオマーカー市場レポート：プロファイリング技術、バイオ分子、がんタイプ、用途、エンドユーザー、地域別2024-2032

世界のがんバイオマーカー市場の市場規模は、2023年に279億米ドルに達しました。今後、IMARC Groupは、市場が2032年までに770億米ドルに達し、2024年から2032年の間に11.7%の成長率（CAGR）を示すと予測しています。がん罹患率の上昇、個別化医療の進歩、ゲノム、プロテオミクス、バイオインフォマティクスなどの技術における著しい革新、コンパニオン診断薬に対する需要の増大、高齢化人口の増加などが市場を推進する主な要因の一部です。

がんバイオマーカーとは、体内に存在し、がんの存在、進行、特徴に関する貴重な情報を提供する特定の分子や物質のことです。これらのバイオマーカーは、様々な種類のがんの早期発見、診断、治療モニタリング、予後予測に役立つことで、腫瘍学の分野で重要な役割を果たしています。バイオマーカーは通常、血液、尿、組織、その他の体液中に存在します。がんバイオマーカーの同定と解析には、ゲノミクス、プロテオミクス、メタボロミクスなどの高度な技術が必要です。これらの技術により、研究者やヘルスケア専門家は分子レベルでの微妙な変化を検出することができ、がんの発生や治療に対する反応についての洞察を得ることができます。特定のバイオマーカーのレベルを測定することで、臨床医は個々の患者に合わせた治療計画を立てることができ、より的を絞った治療と転帰の改善につながります。

世界中で様々な種類のがんの有病率が増加していることが、重要な推進力となっています。がん患者数の増加に伴い、バイオマーカーのような正確で早期診断ツールの需要が高まっています。さらに、バイオマーカーは非侵襲的ながん検出・モニタリング方法を提供し、患者の不快感を軽減し、頻繁な評価を可能にします。この利便性が、患者の受け入れと臨床での採用の両方を促進しています。これ以外にも、早期発見は生存率を向上させるために極めて重要です。がんのバイオマーカーは、がんを最も初期の段階で発見することを可能にし、タイムリーな介入と治癒の可能性のある治療を可能にします。このほか、患者にとって最も効果的な治療法の決定に役立つコンパニオン診断の需要が、バイオマーカー市場の成長を促進しています。これに伴い、世界の高齢化によりがんに罹患しやすくなっています。この人口動向は、バイオマーカーが極めて重要な役割を果たす診断・治療アプローチの改善の必要性を高めています。さらに、ゲノミクス、プロテオミクス、バイオインフォマティクスなどの技術の急速な進歩は、がんバイオマーカーの発見と解析に革命をもたらしています。これらの技術は、より高い感度と特異性を持つ新規バイオマーカーの同定を可能にしています。さらに、個別化医療へのシフトがバイオマーカーの需要を高めています。バイオマーカーは、各患者のがんに特有の遺伝子、分子、プロテオミクス的シグネチャーの同定を可能にし、標的治療を容易にし、治療成績を向上させるからです。

がんバイオマーカー市場傾向/促進要因：

世界のがん罹患率の増加は、市場に明るい展望をもたらしています。バイオマーカーは、がんの早期発見や治療・管理中に、転帰を正確かつ確実に予測するために広く利用されています。これに伴い、汚染レベルの上昇、喫煙動向、摂取習慣の悪化による肺がん罹患率の増加が、市場の成長を増大させています。さらに、次世代シーケンシング（NGS）、ポリメラーゼ連鎖反応（PCR）、遺伝子発現プロファイリング（マイクロアレイ）、治療後のがん再発予測を支援する人工知能（AI）など、遺伝子バイオマーカー探索におけるさまざまな技術進歩が、市場成長に弾みをつけています。さらに、早期診断の重要性に関するヘルスケア専門家や患者の意識の高まりや、標準的な診断法の欠如によるがん治療の個別化医療への大きなシフトが、市場成長に好影響を与えています。その他の要因としては、ヘルスケア産業の著しい成長、広範な研究開発（R&D）活動、医薬品開発プロセスを強化するためのさまざまな政府イニシアチブの実施などが挙げられ、市場の成長を後押しすると予想されます。

がん罹患率の上昇

世界保健機関（WHO）は、ライフスタイルの変化、環境暴露、高齢化などの要因から、がん患者の負担が増加していると報告しています。この急増により、治療が最も効果的な早期段階でがんを発見できる診断ツールの改善が必要とされています。がんのバイオマーカーは、微妙な分子変化を同定する能力を持ち、早期発見とリスク評価を可能にします。これにより、ヘルスケア専門家は、患者の転帰を最適化し、オーダーメイドの治療計画を立案することができます。がんの罹患率が上昇を続ける中、バイオマーカーのような正確で効率的な診断ソリューションに対する需要は、今後も増加の一途をたどると予想されます。

個別化医療の進歩

それぞれのがんは、遺伝的・分子的特徴に左右されるユニークなものです。この複雑さゆえに、個々のがん特有の特性に対応したオーダーメイドの治療アプローチが必要となります。バイオマーカーは、このような複雑さを知る窓を提供し、臨床医が疾患の原因となる正確な分子変化を標的とした治療法を選択することを可能にします。治療法選択における試行錯誤を最小限に抑えることで、個別化医療は治療効果を高めると同時に副作用を軽減します。このアプローチは、患者の遺伝的・分子的プロファイルを迅速に解析できる高度な技術が利用できるようになったため、支持を集めています。個別化医療が脚光を浴びるにつれ、治療の意思決定を導くバイオマーカーの需要は拡大し続けると思われます。

重要な技術革新

次世代シーケンシング、質量分析、マイクロアレイ分析などのハイスループット技術の登場により、潜在的なバイオマーカーを同定・分析する能力が飛躍的に向上しました。これらの手法により、特定の遺伝子変異、エピジェネティックな変化、異なるがん種を示すタンパク質の発現パターンを同定することが可能となった。さらに、バイオインフォマティクス・ツールは膨大なデータセットの解釈を容易にし、新規バイオマーカー候補の発見に役立ちます。このような技術の進歩は、バイオマーカーの発見を早めるだけでなく、その感度と特異性を高め、臨床使用における信頼性を高める。テクノロジーが進化し続けるにつれて、有効ながんバイオマーカーのプールは拡大し、がんの診断と治療の展望がさらに形作られることが期待されます。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界のがんバイオマーカー市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：プロファイリング技術

• オミック技術
  • 市場動向
  • 市場予測
• イメージング技術
  • 市場動向
  • 市場予測
• 免疫測定
  • 市場動向
  • 市場予測
• 細胞遺伝学
  • 市場動向
  • 市場予測

第7章 市場内訳：バイオ分子

• 遺伝子バイオマーカー
  • 市場動向
  • 市場予測
• タンパク質バイオマーカー
  • 市場動向
  • 市場予測
• 糖質バイオマーカー
  • 市場動向
  • 市場予測

第8章 市場内訳：がんのタイプ別

• 乳がん
  • 市場動向
  • 市場予測
• 肺がん
  • 市場動向
  • 市場予測
• 大腸がん
  • 市場動向
  • 市場予測
• 前立腺がん
  • 市場動向
  • 市場予測
• 胃がん
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第9章 市場内訳：用途別

• 診断
  • 市場動向
  • 市場予測
• 予測
  • 市場動向
  • 市場予測
• リスクアセスメント
  • 市場動向
  • 市場予測
• 医薬品の発見と開発
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第10章 市場内訳：エンドユーザー別

• 病院
  • 市場動向
  • 市場予測
• 学術調査機関
  • 市場動向
  • 市場予測
• 外来手術センター
  • 市場動向
  • 市場予測
• 診断検査室
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第11章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第12章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第15章 価格分析

第16章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Becton Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • General Electric Company
  • Illumina Inc.
  • Qiagen N.V.
  • Sino Biological Inc.
  • Thermo Fisher Scientific Inc.

List of Figures

• Figure 1: Global: Cancer Biomarkers Market: Major Drivers and Challenges
• Figure 2: Global: Cancer Biomarkers Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Cancer Biomarkers Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 4: Global: Cancer Biomarkers Market: Breakup by Profiling Technology (in %), 2023
• Figure 5: Global: Cancer Biomarkers Market: Breakup by Biomolecule (in %), 2023
• Figure 6: Global: Cancer Biomarkers Market: Breakup by Cancer Type (in %), 2023
• Figure 7: Global: Cancer Biomarkers Market: Breakup by Application (in %), 2023
• Figure 8: Global: Cancer Biomarkers Market: Breakup by End User (in %), 2023
• Figure 9: Global: Cancer Biomarkers Market: Breakup by Region (in %), 2023
• Figure 10: Global: Cancer Biomarkers (Omic Technologies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 11: Global: Cancer Biomarkers (Omic Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 12: Global: Cancer Biomarkers (Imaging Technologies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: Cancer Biomarkers (Imaging Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: Cancer Biomarkers (Immunoassays) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: Cancer Biomarkers (Immunoassays) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: Cancer Biomarkers (Cytogenetics) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: Cancer Biomarkers (Cytogenetics) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: Cancer Biomarkers (Genetic Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: Cancer Biomarkers (Genetic Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: Global: Cancer Biomarkers (Protein Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: Global: Cancer Biomarkers (Protein Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Global: Cancer Biomarkers (Glyco-Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Global: Cancer Biomarkers (Glyco-Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Global: Cancer Biomarkers (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 25: Global: Cancer Biomarkers (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 26: Global: Cancer Biomarkers (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 27: Global: Cancer Biomarkers (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 28: Global: Cancer Biomarkers (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 29: Global: Cancer Biomarkers (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 30: Global: Cancer Biomarkers (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 31: Global: Cancer Biomarkers (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 32: Global: Cancer Biomarkers (Stomach Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 33: Global: Cancer Biomarkers (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 34: Global: Cancer Biomarkers (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 35: Global: Cancer Biomarkers (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 36: Global: Cancer Biomarkers (Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 37: Global: Cancer Biomarkers (Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 38: Global: Cancer Biomarkers (Prognostics) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 39: Global: Cancer Biomarkers (Prognostics) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 40: Global: Cancer Biomarkers (Risk Assessment) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 41: Global: Cancer Biomarkers (Risk Assessment) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 42: Global: Cancer Biomarkers (Drug Discovery and Development) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 43: Global: Cancer Biomarkers (Drug Discovery and Development) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 44: Global: Cancer Biomarkers (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 45: Global: Cancer Biomarkers (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 46: Global: Cancer Biomarkers (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 47: Global: Cancer Biomarkers (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 48: Global: Cancer Biomarkers (Academic and Research Institutions) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 49: Global: Cancer Biomarkers (Academic and Research Institutions) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 50: Global: Cancer Biomarkers (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 51: Global: Cancer Biomarkers (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 52: Global: Cancer Biomarkers (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 53: Global: Cancer Biomarkers (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 54: Global: Cancer Biomarkers (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 55: Global: Cancer Biomarkers (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 56: North America: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 57: North America: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 58: United States: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 59: United States: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 60: Canada: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 61: Canada: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 62: Asia-Pacific: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 63: Asia-Pacific: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 64: China: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 65: China: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 66: Japan: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 67: Japan: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 68: India: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 69: India: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 70: South Korea: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 71: South Korea: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 72: Australia: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 73: Australia: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 74: Indonesia: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 75: Indonesia: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 76: Others: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 77: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 78: Europe: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 79: Europe: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 80: Germany: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 81: Germany: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 82: France: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 83: France: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 84: United Kingdom: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 85: United Kingdom: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 86: Italy: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 87: Italy: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 88: Spain: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 89: Spain: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 90: Russia: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 91: Russia: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 92: Others: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 93: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 94: Latin America: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 95: Latin America: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 96: Brazil: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 97: Brazil: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 98: Mexico: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 99: Mexico: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 100: Others: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 101: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 102: Middle East and Africa: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
• Figure 103: Middle East and Africa: Cancer Biomarkers Market: Breakup by Country (in %), 2023
• Figure 104: Middle East and Africa: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 105: Global: Cancer Biomarkers Industry: SWOT Analysis
• Figure 106: Global: Cancer Biomarkers Industry: Value Chain Analysis
• Figure 107: Global: Cancer Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Cancer Biomarkers Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Cancer Biomarkers Market Forecast: Breakup by Profiling Technology (in Million US$), 2024-2032
• Table 3: Global: Cancer Biomarkers Market Forecast: Breakup by Biomolecule (in Million US$), 2024-2032
• Table 4: Global: Cancer Biomarkers Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
• Table 5: Global: Cancer Biomarkers Market Forecast: Breakup by Application (in Million US$), 2024-2032
• Table 6: Global: Cancer Biomarkers Market Forecast: Breakup by End User (in Million US$), 2024-2032
• Table 7: Global: Cancer Biomarkers Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 8: Global: Cancer Biomarkers Market: Competitive Structure
• Table 9: Global: Cancer Biomarkers Market: Key Players

The global cancer biomarkers market size reached US$ 27.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 77.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.7% during 2024-2032.The rising cancer incidences, advancements in personalized medicine, significant innovations in technologies such as genomics, proteomics, and bioinformatics, augmenting demand for companion diagnostics, and increasing aging population some of the major factors propelling the market.

Cancer biomarkers are specific molecules or substances that can be found in the body and provide valuable information about the presence, progression, or characteristics of cancer. These biomarkers play a crucial role in the field of oncology by aiding in the early detection, diagnosis, treatment monitoring, and prognosis of various types of cancer. They are typically present in blood, urine, tissues, or other bodily fluids. The identification and analysis of cancer biomarkers involve advanced techniques such as genomics, proteomics, and metabolomics. These techniques enable researchers and healthcare professionals to detect subtle changes at the molecular level, which can provide insights into the development of cancer and its response to treatments. By measuring the levels of specific biomarkers, clinicians can tailor treatment plans to individual patients, leading to more targeted therapies and improved outcomes.

The increasing prevalence of various types of cancers across the globe is a significant driver. As the number of cancer cases grows, the demand for accurate and early diagnostic tools, like biomarkers, intensifies. Additionally, biomarkers offer non-invasive methods of cancer detection and monitoring, reducing patient discomfort and enabling frequent assessments. This convenience is driving both patient acceptance and clinical adoption. Other than this, early detection is crucial for improving survival rates. Cancer biomarkers allow for the detection of cancers at their earliest stages, enabling timely intervention and potentially curative treatments. Besides this, the demand for companion diagnostics, which help determine the most effective treatment for a patient, is fostering the growth of the biomarkers market. In line with this, the global aging population is more susceptible to cancer. This demographic trend is driving the need for improved diagnostic and therapeutic approaches, in which biomarkers play a pivotal role. Furthermore, rapid advancements in technologies such as genomics, proteomics, and bioinformatics have revolutionized cancer biomarker discovery and analysis. These technologies enable the identification of novel biomarkers with higher sensitivity and specificity. Moreover, the shift toward personalized medicine has escalated the demand for biomarkers as they enable the identification of specific genetic, molecular, and proteomic signatures unique to each patient's cancer, facilitating targeted therapies and improving treatment outcomes.

Cancer Biomarkers Market Trends/Drivers:

The increasing prevalence of cancer across the globe is creating a positive outlook for the market. Biomarkers are widely used for early cancer detection and during treatment and management to accurately and reliably predict outcomes. In line with this, the increasing incidences of lung cancer due to the upsurge in pollution levels, smoking trends and poor ingestion habits is augmenting the market growth. Moreover, various technological advancements in genetic biomarker discovery, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), gene expression profiling (microarray), and the artificial inelegance (AI) that assist in predicting the recurrence of cancer after treatment, are providing an impetus to the market growth. Additionally, the increasing awareness amongst healthcare professionals and patients about the importance of early diagnosis and the significant shift toward personalized medicine for cancer treatment due to the lack of standard diagnosis is favoring the market growth. Other factors, including the significant growth in the healthcare industry, extensive research and development (R&D) activities and the implementation of various government initiatives for enhancing the drug development processes, are anticipated to drive the market toward growth.

Rising Cancer Incidence

The World Health Organization (WHO) reports a growing burden of cancer cases, attributed to factors such as lifestyle changes, environmental exposures, and an aging population. This surge necessitates improved diagnostic tools that can detect cancer at its earliest stages, when treatment is most effective. Cancer biomarkers, with their ability to identify subtle molecular changes, enable early detection and risk assessment. This empowers healthcare professionals to devise tailored treatment plans, optimizing patient outcomes. As cancer prevalence continues to escalate, the demand for accurate and efficient diagnostic solutions like biomarkers is expected to remain on an upward trajectory.

Advancements in Personalized Medicine

Each cancer is unique, driven by distinct genetic and molecular characteristics. This complexity demands tailored treatment approaches that address the specific attributes of an individual's cancer. Biomarkers offer a window into these intricacies, allowing clinicians to select therapies that target the precise molecular alterations driving the disease. By minimizing trial and error in treatment selection, personalized medicine enhances treatment efficacy while reducing adverse effects. This approach has gained traction due to the availability of advanced technologies that can rapidly analyze a patient's genetic and molecular profile. As personalized medicine gains prominence, the demand for biomarkers that guide treatment decisions will continue to grow.

Significant Technological Innovations

The advent of high-throughput techniques such as next-generation sequencing, mass spectrometry, and microarray analysis has exponentially increased our ability to identify and analyze potential biomarkers. These methods enable the identification of specific genetic mutations, epigenetic changes, and protein expression patterns that are indicative of different cancer types. Moreover, bioinformatics tools facilitate the interpretation of vast datasets, aiding in the discovery of novel biomarker candidates. These technological advancements not only expedite biomarker discovery but also enhance their sensitivity and specificity, making them more reliable for clinical use. As technology continues to evolve, it is anticipated that the pool of validated cancer biomarkers will expand, further shaping the landscape of cancer diagnosis and treatment.

Cancer Biomarkers Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global cancer biomarkers market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on profiling technology, biomolecule, cancer type, application, and end user.

Breakup by Profiling Technology:

Omic Technologies

Imaging Technologies

Immunoassays

Cytogenetics

The report has provided a detailed breakup and analysis of the market based on the profiling technology. This includes omic technologies, imaging technologies, immunoassays, and cytogenetics.

Omic technologies, encompassing genomics, proteomics, and metabolomics, play a pivotal role in cancer biomarker discovery and profiling. Genomic analysis reveals alterations in DNA sequences, identifying mutations and genetic variations associated with cancer development. Proteomics delves into the intricate world of proteins, identifying biomarkers by studying their expression levels, modifications, and interactions. Metabolomics focuses on small molecule metabolites, shedding light on metabolic pathways disrupted in cancer. These omic approaches provide a comprehensive understanding of the molecular intricacies underlying cancer, enabling the identification of potential biomarkers with high precision. Their ability to uncover subtle changes in genes, proteins, and metabolites makes omic technologies indispensable in the quest for reliable cancer biomarkers, enhancing diagnostic accuracy and paving the way for targeted therapies.

Techniques like positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) provide detailed anatomical and functional information. These technologies enable the visualization of tumors, their growth patterns, and interactions with surrounding tissues. Molecular imaging techniques, a subset of imaging technologies, utilize specific tracers to visualize molecular changes within tumors. This aids in identifying unique biomarkers expressed on cancer cells. Imaging-based biomarker profiling not only aids in accurate diagnosis but also assists in treatment planning and monitoring. As imaging technologies continue to advance, their role in non-invasive biomarker identification and real-time monitoring of treatment responses becomes increasingly integral.

Enzyme-linked immunosorbent assays (ELISA) and multiplex immunoassays measure the concentration of specific proteins, including biomarkers indicative of various cancers. Their high sensitivity and ability to analyze multiple analytes simultaneously make immunoassays invaluable in cancer diagnosis, prognosis, and therapeutic monitoring. Immunoassays are particularly well-suited for measuring soluble proteins and antigens present in blood or other bodily fluids. The advent of novel immunoassay platforms, such as bead-based and microfluidic systems, further enhances their capabilities. Immunoassay-based biomarker profiling not only aids in clinical decision-making but also expedites the development of targeted therapies by identifying patients likely to respond favorably to specific treatments.

Breakup by Biomolecule:

Genetic Biomarkers

Protein Biomarkers

Glyco-Biomarkers

Genetic biomarkers hold the largest share in the market

A detailed breakup and analysis of the market based on the biomolecule has also been provided in the report. This includes genetic biomarkers, protein biomarkers, and glycol-biomarkers. According to the report, genetic biomarkers accounted for the largest market share.

Genetic biomarkers offer insights into an individual's genetic predisposition, mutations, and variations that contribute to disease development. The advent of advanced genomic sequencing technologies has revolutionized our ability to decode the genetic code, identifying specific gene alterations associated with various cancers. Genetic biomarkers not only facilitate early cancer detection but also guide personalized treatment strategies. By pinpointing genetic mutations driving a particular cancer, clinicians can tailor therapies to target these specific genetic anomalies, thereby enhancing treatment efficacy while minimizing adverse effects. Moreover, genetic biomarkers play a crucial role in the development of precision medicine, where treatments are tailored to a patient's genetic profile.

Breakup by Cancer Type:

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Stomach Cancer

Others

Lung cancer dominates the market

The report has provided a detailed breakup and analysis of the market based on the cancer type. This includes breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, and others. According to the report, lung cancer represented the largest segment.

Lung cancer holds a significant global prevalence, ranking among the leading causes of cancer-related deaths. The strong association between lung cancer and smoking, along with environmental factors, contributes to its widespread occurrence. Furthermore, advancements in diagnostic technologies, including imaging and molecular profiling, have improved lung cancer detection and classification. This has led to a higher number of diagnosed cases, contributing to the segment's prominence. Additionally, the complex nature of lung cancer, characterized by diverse subtypes like non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), necessitates targeted therapies based on biomarker profiles. This drives research and innovation, fostering the development of precision medicine approaches tailored to specific lung cancer subtypes.

Breakup by Application:

Diagnostics

Prognostics

Risk Assessment

Drug Discovery and Development

Others

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes diagnostics, prognostics, risk assessment, drug discovery and development, and others.

Cancer biomarkers play a critical role in enabling early and accurate cancer detection. By identifying specific molecular signatures associated with various cancer types, biomarkers assist in pinpointing the presence of cancer at its initial stages. This facilitates timely intervention, ultimately leading to improved patient outcomes. Biomarker-based diagnostics encompass a range of techniques, including blood tests, imaging, and molecular assays, which collectively contribute to effective and non-invasive cancer detection.

By analyzing specific biomarkers, clinicians can gauge the aggressiveness of the cancer, assess the risk of recurrence, and estimate patient survival rates. These insights guide treatment planning, allowing for tailored therapies that match the anticipated disease trajectory. Prognostic biomarkers contribute to informed decision-making, enabling patients and healthcare providers to make choices aligned with individual prognosis.

These biomarkers enable early screening of individuals at elevated risk due to genetic, environmental, or lifestyle factors. By identifying those at risk, healthcare professionals can implement targeted surveillance, preventive measures, and lifestyle interventions to reduce the likelihood of cancer development. Risk management based on biomarkers empowers proactive healthcare strategies that emphasize prevention and early intervention.

Breakup by End User:

Hospitals

Academic and Research Institutions

Ambulatory Surgical Centers

Diagnostic Laboratories

Others

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, academic and research institutions, ambulatory surgical centers, diagnostic laboratories, and others.

With their comprehensive range of medical services and infrastructure, hospitals serve as essential hubs for cancer diagnosis, treatment, and management. Biomarker-based tests are seamlessly integrated into hospital workflows, facilitating timely and accurate cancer diagnosis. Hospitals also offer the necessary facilities for patient monitoring and follow-up, making them central to cancer care. The demand for biomarkers in hospitals is driven by the need for efficient diagnostic tools that aid in early detection, prognosis, and treatment decision-making.

These institutions conduct in-depth research to identify and validate novel biomarkers, contributing to the expansion of our understanding of cancer biology. They also develop cutting-edge technologies and methodologies for biomarker discovery and analysis. Academic institutions serve as platforms for training the next generation of researchers, clinicians, and professionals who will drive biomarker-related research and applications. Additionally, academic collaborations often lead to the development of innovative diagnostic and therapeutic approaches, further enriching the biomarkers market.

These centers provide outpatient surgical and medical procedures, including cancer diagnostics and treatment. ASCs offer efficient and convenient options for patients who require biomarker-based tests, minimizing the need for hospitalization. They cater to patients seeking specialized care in a more streamlined and patient-centered environment. As the trend towards outpatient care continues to grow, ambulatory surgical centers are increasingly adopting biomarker-based diagnostic and treatment methods, contributing to their significance within the market ecosystem.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for cancer biomarkers.

North America possesses a well-established healthcare infrastructure with advanced medical facilities, research centers, and academic institutions. This provides a conducive environment for the integration of biomarker-based diagnostics and treatments into clinical practice. Additionally, substantial investments in cancer research and healthcare technology contribute to the continuous advancement of biomarker discovery and validation. This, coupled with a strong emphasis on personalized medicine, drives the demand for biomarker-driven approaches in patient care. Moreover, North America's proactive regulatory landscape, with agencies like the FDA, fosters the validation and approval of new biomarkers, ensuring their safety and efficacy. This regulatory support instills confidence among healthcare professionals and encourages the adoption of biomarker-based tests. Besides this, a higher awareness of cancer prevention, early detection, and treatment options within the population further fuels the demand for biomarker-based solutions. The presence of a substantial patient pool and a robust pharmaceutical industry also play a pivotal role in the region's dominance in the cancer biomarkers market.

Competitive Landscape:

Major players invest heavily in R&D to identify and validate new biomarkers. This involves extensive laboratory research, clinical trials, and collaborations with academic institutions to discover biomarkers that offer higher accuracy and specificity in cancer detection and monitoring. Additionally, collaboration between biotechnology firms, pharmaceutical companies, research institutions, and healthcare providers accelerates the translation of biomarker discoveries into practical applications. Partnerships facilitate the development of novel diagnostics and therapies that incorporate biomarker information. Other than this, key players continually innovate by adopting and developing cutting-edge technologies, such as next-generation sequencing, liquid biopsies, and advanced imaging techniques. These innovations enhance biomarker detection sensitivity, allowing for earlier and more accurate cancer diagnoses. Besides this, leading firms are focusing on developing companion diagnostics that identify patients most likely to respond to specific treatments. This approach optimizes treatment selection, leading to better patient outcomes and reduced healthcare costs. In line with this, key market players are driving the shift toward personalized medicine by utilizing biomarker information to tailor treatments to individual patients. This approach improves treatment efficacy and minimizes adverse effects. Furthermore, collaboration with regulatory authorities, such as the FDA, ensures that biomarker-based tests meet rigorous standards for accuracy and safety. Regulatory approvals enhance trust in these tests among healthcare professionals and patients.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

Agilent Technologies Inc.

Becton Dickinson and Company

bioMerieux SA

Danaher Corporation

F. Hoffmann-La Roche AG

General Electric Company

Illumina Inc.

Qiagen N.V.

Sino Biological Inc.

Thermo Fisher Scientific Inc.

Recent Developments:

Thermos Fisher Scientific Inc. has recently entered into a significant companion diagnostic agreement with Chugai Pharmaceutical Co. Ltd. This collaboration holds strategic importance within the pharmaceutical and diagnostic sectors. Through this agreement, both companies aim to combine their expertise to enhance the development and availability of companion diagnostics. Thermo Fisher's prowess in cutting-edge scientific solutions and Chugai Pharmaceutical's extensive experience in pharmaceuticals complement each other, fostering the creation of advanced diagnostic tools.

Agilent Technologies Inc. introduced a noteworthy initiative in the form of a Biomarker Pathologist Training Program. This program is a significant step in the field of pathology and biomarker research. Through this endeavor, Agilent is taking a leadership role in promoting education and skill development within the domain of biomarker analysis.

Illumina Inc. embarked on a significant collaborative endeavor by forming a co-development partnership with SomaLogic. This partnership represents a pivotal moment in the landscape of biomarker research and clinical advancements. Illumina, renowned for its pioneering work in next-generation sequencing (NGS), has joined forces with SomaLogic, a distinguished name in the realm of protein biomarker discovery.

Key Questions Answered in This Report

• 1. What was the size of the global cancer biomarkers market in 2023?
• 2. What is the expected growth rate of the global cancer biomarkers market during 2024-2032?
• 3. What are the key factors driving the global cancer biomarkers market?
• 4. What has been the impact of COVID-19 on the global cancer biomarkers market?
• 5. What is the breakup of the global cancer biomarkers market based on the biomolecule?
• 6. What is the breakup of the global cancer biomarkers market based on the cancer type?
• 7. What are the key regions in the global cancer biomarkers market?
• 8. Who are the key players/companies in the global cancer biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cancer Biomarkers Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Profiling Technology

• 6.1 Omic Technologies
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Imaging Technologies
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Immunoassays
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Cytogenetics
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Biomolecule

• 7.1 Genetic Biomarkers
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Protein Biomarkers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Glyco-Biomarkers
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Cancer Type

• 8.1 Breast Cancer
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Lung Cancer
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Colorectal Cancer
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Prostate Cancer
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Stomach Cancer
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Others
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast

9 Market Breakup by Application

• 9.1 Diagnostics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Prognostics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Risk Assessment
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Drug Discovery and Development
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Others
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by End User

• 10.1 Hospitals
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Academic and Research Institutions
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Ambulatory Surgical Centers
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Diagnostic Laboratories
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Others
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Abbott Laboratories
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Agilent Technologies Inc.
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
    • 16.3.2.4 SWOT Analysis
  • 16.3.3 Becton Dickinson and Company
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
    • 16.3.3.4 SWOT Analysis
  • 16.3.4 bioMerieux SA
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 Danaher Corporation
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 F. Hoffmann-La Roche AG
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 SWOT Analysis
  • 16.3.7 General Electric Company
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Illumina Inc.
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis
  • 16.3.9 Qiagen N.V.
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 Sino Biological Inc.
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
  • 16.3.11 Thermo Fisher Scientific Inc.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
    • 16.3.11.3 Financials
    • 16.3.11.4 SWOT Analysis